- Home
- PRGS vs AUPH Comparison
PRGS vs AUPH Comparison
Compare PRGS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- AUPH
- Stock Information
- Founded
- PRGS 1981
- AUPH 1993
- Country
- PRGS United States
- AUPH Canada
- Employees
- PRGS N/A
- AUPH N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- PRGS Technology
- AUPH Health Care
- Exchange
- PRGS Nasdaq
- AUPH Nasdaq
- Market Cap
- PRGS 1.8B
- AUPH 1.6B
- IPO Year
- PRGS 1991
- AUPH 1999
- Fundamental
- Price
- PRGS $42.86
- AUPH $14.45
- Analyst Decision
- PRGS Strong Buy
- AUPH Buy
- Analyst Count
- PRGS 5
- AUPH 2
- Target Price
- PRGS $68.00
- AUPH $16.00
- AVG Volume (30 Days)
- PRGS 629.8K
- AUPH 1.6M
- Earning Date
- PRGS 09-29-2025
- AUPH 11-04-2025
- Dividend Yield
- PRGS N/A
- AUPH N/A
- EPS Growth
- PRGS N/A
- AUPH N/A
- EPS
- PRGS 1.09
- AUPH 0.55
- Revenue
- PRGS $940,126,000.00
- AUPH $265,808,000.00
- Revenue This Year
- PRGS $32.42
- AUPH $17.33
- Revenue Next Year
- PRGS $1.44
- AUPH $14.31
- P/E Ratio
- PRGS $39.21
- AUPH $26.27
- Revenue Growth
- PRGS 31.41
- AUPH 20.62
- 52 Week Low
- PRGS $40.29
- AUPH $6.55
- 52 Week High
- PRGS $70.56
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- PRGS 43.08
- AUPH 74.91
- Support Level
- PRGS $41.92
- AUPH $11.96
- Resistance Level
- PRGS $43.44
- AUPH $16.20
- Average True Range (ATR)
- PRGS 1.21
- AUPH 0.70
- MACD
- PRGS -0.35
- AUPH 0.29
- Stochastic Oscillator
- PRGS 28.67
- AUPH 64.26
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.